Bulletin
Investor Alert

New York Markets Close in:

Market Snapshot Winners and Losers

Cyclo Therapeutics Inc.

NAS: CYTH

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Cyclo Therapeutics Inc.

Market open

 --Real time quotes

Feb 2, 2023, 12:33 p.m.

CYTH
/zigman2/quotes/207006339/composite

$

1.86

Change

-0.10 -5.05%

Volume

Volume 73,791

Real time quotes

/zigman2/quotes/207006339/composite

Previous close

$ 1.96

$ 1.86

Change

-0.10 -5.05%

Day low

Day high

$1.85

$2.09

Open

52 week low

52 week high

$0.91

$4.04

Open

Company Description

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1...

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

Valuation

Price to Sales Ratio

14.98

Price to Book Ratio

2.00

Enterprise Value to EBITDA

-0.01

Enterprise Value to Sales

0.07

Efficiency

Total Asset Turnover

0.09

Liquidity

Current Ratio

5.07

Quick Ratio

5.01

Cash Ratio

4.34

Profitability

Gross Margin

-152.96

Operating Margin

-901.15

Pretax Margin

-900.94

Net Margin

-900.94

Return on Assets

-84.77

Return on Equity

-109.37

Return on Total Capital

-107.89

Capital Structure

Total Debt to Total Assets

0.88

Officers and Executives

Name Age Officer Since Title
Mr. Nathan Scott Fine 64 2014 Executive Chairman & Chief Executive Officer
Dr. Jeffrey L. Tate 61 2010 Director, Chief Operating & Quality Officer
Mr. Joshua M. Fine 39 2014 Chief Financial Officer & Secretary
Dr. Lise Lund Kjems - 2021 Chief Medical Officer
Mr. Michael Lisjak 46 2019 Senior Vice President-Business Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
11/25/2020 Joshua M. Fine
Chief Financial Officer 		15,000   Acquisition at $0.08 per share. 1,200
11/23/2020 Joshua M. Fine
Chief Financial Officer 		10,000   Acquisition at $0.08 per share. 800
09/30/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/30/2020 Armistice Capital LLC
5,500   Disposition at $0.13 per share. 715
09/29/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/29/2020 Armistice Capital LLC
5,000   Disposition at $0.14 per share. 700
09/28/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/28/2020 Armistice Capital LLC
4,966   Disposition at $0.13 per share. 645
09/24/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/24/2020 Armistice Capital LLC
38,257   Disposition at $0.13 per share. 4,973
09/23/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/23/2020 Armistice Capital LLC
50,000   Disposition at $0.14 per share. 7,000
09/22/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/22/2020 Armistice Capital LLC
17,000   Disposition at $0.15 per share. 2,550
09/21/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/21/2020 Armistice Capital LLC
100,000   Disposition at $0.15 per share. 15,000
09/16/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/16/2020 Armistice Capital LLC
125,000   Disposition at $0.16 per share. 20,000
/news/latest/company/us/cyth

MarketWatch News on CYTH

  1. Cyclo Therapeutics stock price target cut to $5 from $10 at Maxim Group

    8:36 a.m. Nov. 16, 2022

    - Tomi Kilgore

  2. Cyclo Therapeutics stock price target cut to $16 from $25 at Maxim Group

    6:45 a.m. Oct. 8, 2021

    - Tomi Kilgore

  3. Cyclo Therapeutics stock price target raised to $25 from $12 at Maxim Group

    12:39 p.m. Feb. 9, 2021

    - Tomi Kilgore

  4. Cyclo Therapeutics started at buy with $12 stock price target at Maxim Group

    7:57 a.m. Dec. 17, 2020

    - Tomi Kilgore

/news/nonmarketwatch/company/us/cyth

Other News on CYTH

  1. Cyclo Therapeutics reports Q3 results

    8:16 a.m. Nov. 11, 2022

    - Seeking Alpha

  2. 10-Q: CYCLO THERAPEUTICS, INC.

    5:45 p.m. Nov. 10, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  4. Cyclo Therapeutics (CYTH) Investor Presentation - Slideshow

    2:51 p.m. Aug. 18, 2022

    - Seeking Alpha

  5. 10-Q: CYCLO THERAPEUTICS, INC.

    3:15 p.m. Aug. 15, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  7. Cyclo Therapeutics (CYTH) Investor Presentation - Slideshow

    12:58 p.m. May 26, 2022

    - Seeking Alpha

  8. 10-Q: CYCLO THERAPEUTICS, INC.

    3:11 p.m. May 12, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  9. Hypotheses Underlying Alzheimer's Drug Development

    12:06 p.m. April 26, 2022

    - Seeking Alpha

  10. Pathways Impacting Alzheimer's Disease Drug Development

    4:43 a.m. April 19, 2022

    - Seeking Alpha

  11. Cyclo Therapeutics (CYTH) Investor Presentation - Slideshow

    1:33 p.m. April 1, 2022

    - Seeking Alpha

  12. 10-K: CYCLO THERAPEUTICS, INC.

    4:54 p.m. March 11, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  15. Anti-Amyloid Drugs: The Failure Of Success

    7:04 a.m. Jan. 1, 2022

    - Seeking Alpha

  16. RDHL, ARDX and BRFS among pre market gainers

    8:58 a.m. Dec. 6, 2021

    - Seeking Alpha

  18. SAVA, CEI and EYES among mid-day movers

    12:39 p.m. Nov. 17, 2021

    - Seeking Alpha

  19. Rivian Automotive, DLocal, StoneCo among premarket losers' pack

    8:36 a.m. Nov. 17, 2021

    - Seeking Alpha

  20. Cyclo Therapeutics secures $12M capital through equity raise

    1:52 a.m. Nov. 17, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Cyclo Therapeutics, Inc.

6714 NW 16th Street

Suite B

Gainesville, Florida 32653

Phone

1 3864188060

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$1.59M

Net Income

$-14.29M

Employees

9.00

Annual Report for CYTH

/news/pressrelease/company/us/cyth

Press Releases on CYTH

  11. Cyclo Therapeutics Provides Business Update

    1:02 p.m. Sept. 28, 2022

    - BusinessWire - BZX

  14. Cyclo Therapeutics to Present at the China NPC Association Meeting

    7:05 a.m. Aug. 8, 2022

    - BusinessWire - BZX

  15. Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

    7:05 a.m. July 21, 2022

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.